| 4.19 0.07 (1.7%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.37  |
1-year : | 6.07 |
| Resists | First : | 4.6 |
Second : | 5.2 |
| Pivot price | 4.03 |
|||
| Supports | First : | 3.63 | Second : | 3.02 |
| MAs | MA(5) : | 4.13 |
MA(20) : | 4.12 |
| MA(100) : | 5.06 |
MA(250) : | 5 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 64.7 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 7.17 | Low : | 2.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANNX ] has closed below upper band by 28.5%. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.27 - 4.29 | 4.29 - 4.3 |
| Low: | 4.06 - 4.08 | 4.08 - 4.1 |
| Close: | 4.15 - 4.19 | 4.19 - 4.22 |
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Sun, 27 Sep 2026
Insider Spends US$100k Buying More Shares In Annexon - Simply Wall Street
Sun, 27 Sep 2026
Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX) - Seeking Alpha
Fri, 25 Sep 2026
Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares - gurufocus.com
Fri, 25 Sep 2026
After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan
Thu, 13 Aug 2026
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 190 (M) |
| Shares Float | 164 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 103 (%) |
| Shares Short | 32,870 (K) |
| Shares Short P.Month | 32,580 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.6 % |
| Return on Equity (ttm) | -105.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -193 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -3.71 |
| PEG Ratio | 0 |
| Price to Book value | 3.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|